PER-056-04已完成未知
MULTINATIONAL CLINICAL TRIAL, MULTICENTRIC, PHASE II PROSPECTIVE, RANDOMIZED, PARTIALLY BLIND, OF PARALLEL GROUPS, CONTROLLED WITH AN UNDASMATED ACTIVE COMPARATOR OF DOSE SEARCH AND EVALUATION OF DRUG BAY 59-7939 (DIRECT ORAL INHIBITOR OF FACTOR XA) IN THE TREATMENT OF PATIENTS WITH TRUNBOSIS VENOUS DEEP PROXIMAL ACUTE SYMPTOMATIC (STUDIO ODIXA-DVT)
BAYER S.A.,0 个研究点目标入组 0 人开始时间: 2004年9月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with acute symptomatic proximal deep vein thrombosis.
- •Men or women over 18 years of age.
排除标准
- •Contraindication to comparator drugs
- •Symptomatic Pulmonary embolism
- •Conditions with increased bleeding risk
- •Unstable patients with reduced life expectancy
- •Severe renal impairment
- •Impaired liver function
- •Strong CYP 3A4 inhibitors
- •Platelet aggregation inhibitors (exception: ASA up to 500mg) therapy with anticoagulants or fibrinolytics
- •NSAIDs with half-life > 17 hours
研究者
相似试验
进行中（未招募）
不适用
Multi-center, Multi-national Clinical Trial of the Application of Tissue Repair Cell (TRC) Therapy of Osteonecrosis in the Femur HeadEUCTR2006-001286-42-ESAastrom Biosciences, Inc15
已完成
不适用
Study for reduction of Eye PressureCTRI/2019/06/019564iSTAR Medical SA4
进行中（未招募）
不适用
Study for Reduction of Eye PressureCTRI/2021/02/030922iSTAR Medical SA
进行中（未招募）
1 期
A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancerocally advanced, inflammatory or early stage HER2 positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012019-17-DEF. Hoffmann-La Roche Ltd.225
进行中（未招募）
不适用
A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer. - NDEUCTR2009-012019-17-ITF. Hoffmann - La Roche Ltd225